AREDS2 10-Year Follow-On Study Update: The Role of Nutritional Supplementation in Age-Related Macular Degeneration (CE Monograph)
Activity Description and Purpose
Age-related macular degeneration (AMD) is a multifactorial, chronic, progressive disease that can result in severe vision loss if it progresses to an advanced stage with the development of choroidal neovascularization or geographic atrophy. Findings from the primary analysis of the Age-Related Eye Disease Study 2 led to a recommendation for the use of a specific micronutrient supplement formulation to reduce the risk of progression from intermediate AMD to advanced AMD. Recently reported results from the Age-Related Eye Disease Study 2 follow-on study showed the treatment benefit of the recommended supplement persisted at 10 years. Lifestyle interventions may also reduce the risk of AMD progression, and timely detection of conversion to choroidal neovascularization with appropriate management can improve visual outcomes. The desired results of this educational activity are to help optometrists diagnose AMD, appropriately stage the disease, and understand the role of nutritional supplementation plus other measures that support optimal patient care.
This educational activity is intended for optometrists.
After completing this activity, participants will be better able to:
- Interpret diagnostic imaging to correctly diagnose AMD
- Appraise the clinical relevance of data on vitamins and minerals in the prevention of AMD progression
- Describe appropriate nutritional supplementation for patients with AMD
- Employ patient counseling on lifestyle changes according to risk factors for developing AMD
|Jeffry Gerson, OD (Chair)|
Grin Eye Care
Kansas City VA Medical Center
Kansas City, Missouri
|Steven Ferrucci, OD|
Chief, Optometry Section
Sepulveda VA Medical Center
North Hills, California
Southern California College of Optometry
|Mohammad Rafieetary, OD|
Consultative Optometric Physician
Charles Retina Institute
|Sherrol A. Reynolds, OD|
Associate Professor of Optometry
Nova Southeastern University College of Optometry
Coral Springs, Florida
|Leo Semes, OD|
Professor Emeritus of Optometry and Vision Science
University of Alabama at Birmingham
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Steven Ferrucci, OD, is an advisory board member of MacuLogix, Inc, ScienceBased Health, and Visible Genomics; is on the speakers bureau for CenterVue SpA, Genentech, Inc, Icare USA Inc, Notal Vision, and Regeneron Pharmaceuticals, Inc; and was on the speakers bureau for Alcon and Optovue, Incorporated, within the past 2 years, but those relationships have ended.
Jeffry Gerson, OD, is a consultant for Bausch & Lomb Incorporated and MacuLogix, Inc.
Mohammad Rafieetary, OD, is an advisory board member of Apellis Pharmaceuticals, Heidelberg Engineering GmbH, Iveric Bio, Inc, Notal Vision, Optos, and Regeneron Pharmaceuticals, Inc; is on the speakers bureau for Heidelberg Engineering GmbH, Notal Vision, Optos, Regeneron Pharmaceuticals, Inc, and Spark Therapeutics, Inc; and was an advisory board member of Cardinal Health within the past 2 years, but that relationship has ended.
Sherrol A. Reynolds, OD, is on the speakers bureau for Allergan and VSP.
Leo Semes, OD, is a consultant for MacuLogix, Inc; is an advisory board member of Apellis Pharmaceuticals and EyePromise; is on the speakers bureau for Regeneron Pharmaceuticals, Inc, and ZeaVision LLC; and has individual stock options in ZeaVision LLC.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 80282-TD (Enduring Distance Learning Course)
COPE Course Category: Treatment & Management of Ocular Disease
Disclosure of Commercial Support
This continuing education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated
This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, Bausch & Lomb Incorporated, or Optometric Management.
This CE activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 263
- 2.00 COPE